Pitney Bowes Inc., operates as a technology-driven company that provides SaaS shipping solutions, mailing innovation, and financial services to small businesses, large enterprises, and government entities around the world. It operates through SendTech Solutions and Presort Services segments. The SendTech Solutions segment provides physical and digital shipping and mailing technology solutions, and other applications for sending, tracking and receiving of letters, parcels and flats, supplies, and maintenance services, as well as financing alternatives to finance equipment and product purchases. The Presort Services segment offers mail sortation services, which allow clients to qualify volumes of first-class mail, marketing mail, marketing mail flats, and bound printed matter for postal workshare discounts. It markets its products, solutions, and services through direct and inside sales force, global and regional partner channels, direct mailings, and digital channels. The company was formerly known as Pitney Bowes Postage Meter Company. Pitney Bowes Inc. was incorporated in 1920 and is headquartered in Stamford, Connecticut.

Pitney Bowes Inc.

The latest announcement is out from Paradigm Biopharmaceuticals ( ($AU:PAR) ). Paradigm Biopharmaceuticals Limited has announced the cessation of 2...

Paradigm Biopharmaceuticals Cancels 2 Million Convertible Notes

Paradigm Biopharmaceuticals ( ($AU:PAR) ) has issued an update. Paradigm Biopharmaceuticals has agreed to return US$2 million received under a rece...

Paradigm Returns US$2m to Obsidian Amid Phase 3 Trial Review

Paradigm Biopharmaceuticals ( ($AU:PAR) ) has issued an update. Paradigm Biopharmaceuticals has requested and received a voluntary suspension of tr...

Paradigm Biopharmaceuticals Halts Trading Pending Phase 3 Trial Update

The latest announcement is out from Paradigm Biopharmaceuticals ( ($AU:PAR) ). Paradigm Biopharmaceuticals has appointed Dr Daniel Furtner as Chief...

Paradigm Biopharmaceuticals reshapes medical leadership as Phase 3 osteoarthritis trial advances

Paradigm Biopharmaceuticals ( ($AU:PAR) ) has issued an update. Paradigm Biopharmaceuticals has issued a cleansing notice covering a new tranche of...

Paradigm Biopharmaceuticals issues cleansing notice for new convertible notes tranche

Paradigm Biopharmaceuticals ( ($AU:PAR) ) has provided an update. Paradigm Biopharmaceuticals Limited has notified the market of the issuance of 2,...

Paradigm Biopharmaceuticals Issues 2 Million Unquoted Convertible Notes

Paradigm Biopharmaceuticals ( ($AU:PAR) ) has issued an update. Paradigm Biopharmaceuticals has strengthened its balance sheet by drawing down the ...

Paradigm Secures Further Funding as Knee Osteoarthritis Phase 3 Trial Fully Enrolled

Paradigm Biopharmaceuticals ( ($AU:PAR) ) has shared an update. Paradigm Biopharmaceuticals Limited, an ASX-listed biopharmaceutical company tradin...

Paradigm Biopharmaceuticals Seeks ASX Quotation for 18.9 Million New Shares

POSaBIT Systems ( ($TSE:PBIT) ) has issued an update. POSaBIT Systems has amended its $4.75 million loan agreement with Perga Capital Partners, acc...

POSaBIT Restructures Perga Loan to Cut Interest and Extend Maturity

The latest update is out from Paradigm Biopharmaceuticals ( ($AU:PAR) ). Paradigm Biopharmaceuticals has scheduled an investor lunch briefing in Me...

Paradigm Biopharmaceuticals to Brief Investors on Late-Stage Osteoarthritis Drug

Paradigm Biopharmaceuticals ( ($AU:PAR) ) has provided an update. Paradigm Biopharmaceuticals has lodged its annual corporate governance materials ...

Paradigm Biopharmaceuticals lodges updated ASX corporate governance disclosures

An announcement from Paradigm Biopharmaceuticals ( ($AU:PAR) ) is now available. Paradigm Biopharmaceuticals reported revenue from continuing activ...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	PBI	$16.38	+0.12%	854.20K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	PBI	$16.38	+0.1%	854.20K
3
4
5
6

PBI

Get Pitney Bowes Inc. Data in Excel

Get Pitney Bowes Inc. Data in Excel